The agreement, disclosed in the drugmaker’s latest annual report, ends a probe opened three years ago by the U.S. attorney in Boston. Novartis is accused of donating money to independent foundations that help Medicare beneficiaries pay their out-of-pocket costs for its Gleevec cancer medication and Gilenya multiple sclerosis treatment.
A Novartis spokesman told STAT the payment agreement was a “mutually acceptable resolution” and that “independent copay foundations are legitimate charitable foundations that help patients cover out-of-pockets costs associated with their care.”
Federal prosecutors are more aggressively pursuing drugmakers for donating to programs that provide patients with free medication or copay assistance. Most recently, Alexion Pharmaceuticals disclosed it paid $13 million to resolve claims concerning payments to patient organizations.
Read the full report here.
More articles on pharmacy:
Viewpoint: It’s time for pharma to have its ‘tobacco moment’
Top 10 fatal or harmful prescribing errors
‘Wacky’ rebate system to blame for high patient drug prices, FDA chief says
